Can a daily pill keep mantle cell lymphoma at bay?

NCT ID NCT02242097

Completed Disease control Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

First seen Jun 12, 2026 · Last updated Jun 12, 2026

Summary

This study tested whether a daily drug called ibrutinib can help prevent mantle cell lymphoma from returning after initial chemotherapy. Thirty-seven adults with the disease took ibrutinib for up to three years. Researchers tracked how long the cancer stayed away and monitored side effects to see if this maintenance approach is safe and effective.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONTIGUOUS STAGE II MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Cleveland Clinic

Cleveland, Ohio, 44195, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Northwestern University

Chicago, Illinois, 60611, United States
Northwestern University- Lake Forest Hospital

Lake Forest, Illinois, 60045, United States
University of Utah

Salt Lake City, Utah, 84132, United States

Conditions

Explore the condition pages connected to this study.

CONTIGUOUS STAGE II MANTLE CELL LYMPHOMA NONCONTIGUOUS STAGE II MANTLE CELL LYMPHOMA STAGE I MANTLE CELL LYMPHOMA STAGE III MANTLE CELL LYMPHOMA STAGE IV MANTLE CELL LYMPHOMA